Company intelligence / Profile preview

Novatek Pharmaceuticals

Houston, Texas, United Statesnovatekpharmaceuticals.com ↗

Ownership: Private
Employees: ~500
Development stage: Phase 2

Overview

Novatek Pharmaceuticals is developing NP‑101, a naturally derived immunomodulator from black seed oil. Clinical trials have shown significant effects on T cell populations in cancer patients. A small randomized Phase II trial in outpatient COVID-19 has been published; a larger Phase IIb trial is ongoing. Oncology trials are underway for high-grade neuroendocrine cancers and additional cancer types are planned or enrolling.[10]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules (notably thymoquinone, derived from Nigella Sativa/black seed oil)[1][4][10]Immunomodulatory agents[1][4]
Industry: Biotech

Drug pipeline

3 assets

NP-101

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Novatek Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novatek Pharmaceuticals.

Explore the full profile